The wear and tear of time leaves millions of people struggling with painful, grating osteoarthritis each year. But repairing the cartilage damage at the root of the problem can be a tricky business. Real cartilage does not regenerate naturally, nor do any approved drugs promote its regeneration. Orthotrophix Inc. is working to change that with a new targeted peptide that stimulates cartilage production.
Treatment for osteoarthritis, the most common form of arthritis, has generally been limited to pain control or improved joint lubrication with agents such as hyaluronic acid products, including Sanofi Pharmaceuticals Inc.'s Hyalgan (sodium hyaluronate) or Synvisc (hylan G-F 20). Knee joint replacement is sometimes used to address advanced stages of the disease, and some companies are experimenting with growth factor proteins, but those can be problematic because they're not selective and can lead to undesired side effects such as potential pain.